Adult acute nonlymphocytic leukemias.
For the first two decades, leukemic chemotherapy had little impact on survival. In the past 10 years, however, remission induction therapy has generated complete remissions which last approximately one year in about half to three fourths of those treated, with a seventh in some series alive at 5 years.
D000208:Acute Disease; D000368:Aged; D000740:Anemia / Q000628:therapy; D000741:Anemia, Aplastic / Q000097:blood; D000756:Anemia, Sideroblastic / Q000097:blood; D001803:Blood Transfusion; D016026:Bone Marrow Transplantation; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004351:Drug Resistance; D005260:Female; D006470:Hemorrhage / Q000628:therapy; D006801:Humans; D007167:Immunotherapy; D007938:Leukemia / Q000145:classification* / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000097:blood; D015470:Leukemia, Myeloid, Acute / Q000145:classification; D008297:Male; D008875:Middle Aged; D017713:Platelet Transfusion; D013116:Spinal Cord / Q000002:abnormalities; D013577:Syndrome
D003561:Cytarabine; D003630:Daunorubicin